Seres Therapeutics Inc (MCRB) Quarterly Balance Sheets

Quarterly · GAAP · USD millions
Access MCRB Annual Balance Sheets →
Observing balance sheet movements over recent quarters helps explain how Seres Therapeutics Inc adapts its asset base and funding mix.
Quarterly Report, GAAP in USD millions
ITEM
(Jun 30 2026)
(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Assets
Cash & cash equivalent15.59
Cash & Short-term Investments15.00
Accounts receivable0.27
Other Current Assets25.00
Prepaid Expense And Other Assets Current1.48
Total Current Assets42.35
Equipment/Property/Plant Net61.09
Other Assets, Noncurrent0.00
Operating Lease Right Of Use Asset70.23
Restricted Cash Noncurrent8.67
Total Assets101.59
Liabilities
Accounts Payable, Current AC1.19
Accrued Liabilities And Other Liabilities2.23
Other Liabilities, Current16.62
Total Current Liabilities20.03
Total Long-term Debt0.00
Other liabilities, Noncurrent47.02
Accrued Liabilities And Other Liabilities Current2.86
Operating Lease Liability Current10.87
Total Liabilities67.05
Stockholders' Equity
Common Stock Value0.01
Additional Paid In Capital Common Stock1,022.26
Retained Earnings / Accumulated Deficit-987.74
Other Equity0.00
Common Stockholder's Equity34.53
Total Stockholder's Equity34.53
Liabilities & Stockholder's Equity101.59
4 historic quarters locked

Sign in to unlock the full Seres Therapeutics Inc balance sheet history.

About Seres Therapeutics Inc Quarterly Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC 10-Q filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0001193125-26-334174

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.